First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. - Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; et al. (The oncologist, 2024)